



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsLtd@gmail.com Website : www.concorddrugs.in

To,

Date: 30.05.2022

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2022

Ref: Our Company's letter dated 16.05.2022

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Monday, 30.05.2022 at 4:00 p.m. at the registered office of the company the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2022. **(Enclosed)**
2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2022. **(Enclosed)**

The meeting concluded at **08.00** p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,
For Concord Drugs Limited

S. Nagi Reddy



S. Nagi Reddy
Chairman & Whole time Director
DIN: 01764665





CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March 2022					
[Rs. in Lakhs]					
Particulars	Quarterly ended			Year ended	
	31-Mar-22 (Audited)	31-Dec-21 (unAudited)	31-Mar-21 (Audited)	31-Mar-22 (Audited)	31-Mar-21 (Audited)
I Revenue from Operations					
a. Net sales from Operations	1,546.46	1,344.17	834.63	5,895.648	5,135.70
b. Other Operating Income	2.90	2.77	2.152	10.08	6.46
II Other Income					
III Total Revenue (I+II)	1,548.82	1,346.93	836.78	5,905.73	5,145.16
IV Expenses					
a. Cost of Material Consumed	1,065.71	1,065.06	552.782	4,441.147	4,049.15
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-193.07	15.75	42.560	231.057	168.67
c. Employee Benefit Expenses	160.10	120.30	92.290	489.099	375.55
d. Finance Costs	23.45	18.31	27.486	168.075	142.03
e. Depreciation and Amortisation expense	37.10	29.51	33.223	176.451	136.53
f. Other expenses	447.99	39.39	74.356	637.210	220.35
Total Expenses	1,541.29	1,289.12	822.70	5,680.92	5,092.28
Profit/ (Loss) before Exceptional Item and tax (III-IV)	7.53	57.82	14.087	224.81	52.88
V Exceptional Items	-	-	23.981	-	376.32
VI Profit/ (Loss) before tax (V-VI)	7.53	57.82	38.068	224.805	429.20
VII Tax Expense:					
VIII a. Current tax	4.80	15.68	4.501	65.37	101.03
b. Deferred tax charge/credit	5.14	9.56	0.155	67.12	47.07
IX Profit/ (Loss) for the period (VII-VIII)	2.73	42.14	33.567	159.43	328.17
X Other Comprehensive Income					
Items that will not be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	2.73	42.14	33.567	159.435	328.17
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.38	874.38	874.38	874.38	874.38
Other Equity	1,961.68	1,958.95	1,802.249	1,961.68	1,802.249
XII Earnings per share (of Rs. 10 each)					
XIII a. Basic (in Rs)	0.03	0.48	0.38	1.82	3.75
b. Diluted (in Rs)	0.03	0.48	0.38	1.82	3.75
Notes:					
1	The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.				
2	The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 30th May, 2022				
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.				
4	The results are also available on the website of the Company www.concorddrugs.in				
Place: Hyderabad	 By Order of the Board For Concord Drugs Limited  Managing Director DIN: 01764665				
Date: 30th May, 2022					

**CONCORD DRUGS LIMITED**

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsLtd@gmail.com Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249, Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana			
Audited Balance sheet as at 31st March, 2022 Rs in Lakhs			
Particulars	Note	As At March 31, 2022	As At March 31, 2021
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	1,332.92	1,319.15
(b) Capital Work-in Progress	3	55.39	-
(b) Investment property	3	63.95	63.95
Financial assets			
(a) Loans & Advances	5	3.19	2.64
Other Non current assets	4	-	-
Total Non - Current Assets		1,455.45	1,385.74
Current Assets			
Inventories	7	1,748.99	1,187.18
Financial assets			
(a) investments			
(b) Trade receivables	6	2,285.85	2,072.80
(c) Cash and cash equivalents	8	4.44	3.55
(d) Bank balances other than (c) above	8	2.10	2.10
(e) Other Current Financial Assets	9	10.07	4.42
Other current assets	10	137.61	332.48
Total Current assets		4,189.07	3,602.54
Total Assets		5,644.513	4,988.27
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	874.38	874.38
Other equity	12	1,951.68	1,902.25
Total Equity		2,826.06	2,676.62
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	348.25	375.10
(b) Trade payables			
Deferred tax liabilities, net	14	65.92	67.67
Provisions	15	208.38	208.38
Government Grants	13	-	36.92
Total Non-current liabilities		522.56	688.07
Current liabilities			
Financial liabilities			
(a) Borrowings	16	1,395.17	922.21
(b) Trade payables	17	717.88	314.77
(c) Other Current financial liabilities	18	-	-
Current tax liabilities, net	15	67.13	47.07
Other current liabilities	19	105.72	339.52
Total Current liabilities		2,285.90	1,623.57
Total liabilities		2,808.45	2,311.65
Total Equity and liabilities		5,644.513	4,988.27
For: Pundarikashyam And Associates Chartered Accountants, FRN-011390 SO/- B.Surya Prakasa rao Partner Mno-205125 Place: Hyderabad Date: 30.06.2022		For and on behalf of the Board of Directors of Concord Drugs Limited <i>S. Nani Reddy</i> S. Nani Reddy Managing Director DIN:01764665 <i>S. Koni Reddy</i> Koni Reddy Seelam Executive Director DIN: 02829319	



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana			
Statement of Cash flow for the year ended 31st March , 2022			
Particulars	Rs In Lakhs		
	As at March 31, 2022	As at March 31, 2021	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit Before Tax		224.805	429.20
Adjustments for:			
Profit on sale of Assets			
- Depreciation and amortisation expense	176.45		136.53
Finance costs	141.33		124.53
Interest income	(1.23)		(0.84)
Provision for Gratuity			
		337	
Operating profit before working capital changes		541.36	689.46
Changes in working capital: (Refer Note-4)			
Adjustments for (increase) / decrease in operating assets:			
Financial Assets			
Trade receivables	(213.04)		471.79
Loans and Advances	(0.55)		50.98
Other Non Current assets	-		37.85
Inventories	(561.83)		455.94
Other Current assets	194.87		29.71
Other bank balances	-		0.49
Other Current financial Assets	(5.66)		(0.29)
Adjustments for increase / (decrease) in operating liabilities:			
Trade payables	403.11		(964.85)
Borrowings	-		-
Other current financial liabilities	-		-
Other current liabilities	(233.81)		-
Current tax liabilities, net	20.06		35.16
Provisions	-		(597.60)
Deferred tax on amalgamation	-		-
Cash generated from operations		144.54	208.64
Net income tax paid		(67.12)	(47.07)
Net cash flow from operating activities (A)		77.420	161.57
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital expenditure on fixed assets, including capital advances (Refer Note (ii) below)	(245.61)		(367.40)
Proceeds from maturity of fixed deposits	-		-
- Others	1.23		0.81
Net cash (used in) / flow from investing activities (B)		(244.380)	(366.59)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of equity shares	-		-
Finance costs	(141.33)		(124.53)
Repayment of Borrowings	(126.85)		(27.42)
Repayment of short term Borrowings	472.96		367.92
Govt Grants	(36.92)		(8.61)
Other equity Adjustment	-		-
Net cash flow (used in) financing activities (C)		167.861	207.36
Net (decrease) in Cash and cash equivalents (A+B+C)		0.89	2.34
Cash and cash equivalents at the beginning of the year		3.546	1.21
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-	-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		4.44	3.55
* Comprises:			
Balances with Banks		0.50	0.08
Others		3.94	3.46
		4.44	3.55
As per our report of even date			
For Pundarikashyam And Associates Chartered Accountants Firm Registration No.:0113305		For and on behalf of the Board of Directors of Concord Drugs Limited CIN: L24230TG1995PLC020093	
SD:- B.Surya Prakash Rao Partner M.No - 205325		S. Hari Reddy Managing Director DIN:02794665	S. Kani Reddy Executive Director DIN: 02829319
Place: Hyderabad Date: 30.05.2022			



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana				
Audited Statement Of Standalone Profit and Loss for the Period ended 31st March '22				
Rs in Lakhs				
	Particulars	Note	As at March 31,2022	As at March 31, 2021
I	Revenue from Operations			
	a. Net sales from Operations	20	5,895.648	5,135.70
II	Other Income	21	10.082	9.46
III	Total Revenue (I+II)		5,905.730	5,145.16
IV	Expenses			
	a. Cost of Material Consumed	22	4,441.147	4,049.15
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-231.057	168.67
	c. Employees Benefit Expenses	24	489.099	375.55
	d. Finance Costs	25	168.075	142.03
	e. Depreciation and Amortisation expense	3	176.451	136.53
	f. Other expenses	26	637.210	220.35
	Total Expenses		5,680.92	5,092.28
	Profit/ (Loss) before Exceptional item and tax (III-IV)		224.805	52.88
V	Exceptional Items		-	376.32
VI	Profit/ (Loss) before tax (V+VI)		224.805	429.20
VII	Tax Expense:		65.3704	101.03
VIII	a. Current tax		67.1212	47.07
	b. Deferred tax charge/credit		-1.7508	53.96
IX	Profit/ (Loss) for the period (VII-VIII)		159.4347	328.17
X	Other Comprehensive Income		-	-
	Items that will not be reclassified to profit or loss		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		159.435	328.17
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		874.375	874.38
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		1.82	3.75
	b. Diluted (in Rs)		1.82	3.75

For Pundarikashyam and Associates
Chartered Accountants
FRN- 0113305

SD/-
B. Surya Prakasa Rao
Partner
Mno-205125

Place: Hyderabad
Date: 30.05.2022

For and on behalf of the Board of Directors of
Concord Drugs Limited



S. Nagi Reddy
S. Nagi Reddy
Managing Director
DIN:01764665

S. Koni Reddy
Koni Reddy Seelam
Executive Director
DIN: 02829319



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.
E-mail : concorddrugsitd@gmail.com Website : www.concorddrugs.in

To,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Date: 30.05.2022

Dear Sir,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Nagi Reddy, Chairman & Whole time Director of Concord Drugs Limited hereby declare that the statutory Auditors of the company, M/s. Pundarikashyam and Associates, Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2022.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours sincerely,
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Chairman & Whole time Director
DIN: 01764665





PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar,

Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,

E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CONCORD DRUGS LIMITED,

1. We have audited the accompanying statement of Standalone financial results of Concord Drugs Limited ('the company'), for the three months and year ended March 31,2022('the Statement'), being submitted by the Company pursuant to the requirements of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (the "Listing Regulations").
2. This statement is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act') as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the listing Regulations.Our responsibility is to express an opinion on the Statement based on our audit of such interim consolidated financial statement.
3. We conducted our audit of the Statement in accordance with the Standards on Auditing (SAs) issued by the Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the company's preparation and fair presentation of the statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal financial controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.



We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the statement
- a. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations; and
 - b. gives a true and fair view in conformity with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34") prescribed under Section 133 of the Companies Act 2013 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the three months and year ended March 31, 2022.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S

B. Surya

B. Surya Prakasa
(Partner)
MNo: 205125
UDIN: 22205125AJXVOC7149



Place: Hyderabad
Date: 30.05.2022.